Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

1.

Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.

Tan F, Wahdan-Alaswad R, Yan S, Thiele CJ, Li Z.

Cancer Sci. 2013 Dec;104(12):1586-92. doi: 10.1111/cas.12278. Epub 2013 Oct 21.

PMID:
24011394
[PubMed - indexed for MEDLINE]
2.

MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.

Lovén J, Zinin N, Wahlström T, Müller I, Brodin P, Fredlund E, Ribacke U, Pivarcsi A, Påhlman S, Henriksson M.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1553-8. doi: 10.1073/pnas.0913517107. Epub 2010 Jan 4.

PMID:
20080637
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.

Chevrier L, Meunier AC, Cochaud S, Muller JM, Chadéneau C.

Int J Oncol. 2008 Nov;33(5):1081-9.

PMID:
18949372
[PubMed - indexed for MEDLINE]
4.

Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.

Akter J, Takatori A, Hossain MS, Ozaki T, Nakazawa A, Ohira M, Suenaga Y, Nakagawara A.

Clin Cancer Res. 2011 Nov 1;17(21):6681-92. doi: 10.1158/1078-0432.CCR-11-0313. Epub 2011 Sep 9.

PMID:
21908575
[PubMed - indexed for MEDLINE]
Free Article
5.

Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.

Woo CW, Tan F, Cassano H, Lee J, Lee KC, Thiele CJ.

Pediatr Blood Cancer. 2008 Feb;50(2):208-12.

PMID:
17420990
[PubMed - indexed for MEDLINE]
6.

Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.

Cetinkaya C, Hultquist A, Su Y, Wu S, Bahram F, Påhlman S, Guzhova I, Larsson LG.

Mol Cancer Ther. 2007 Oct;6(10):2634-41.

PMID:
17938259
[PubMed - indexed for MEDLINE]
Free Article
7.

Regulation of MYCN expression in human neuroblastoma cells.

Jacobs JF, van Bokhoven H, van Leeuwen FN, Hulsbergen-van de Kaa CA, de Vries IJ, Adema GJ, Hoogerbrugge PM, de Brouwer AP.

BMC Cancer. 2009 Jul 18;9:239. doi: 10.1186/1471-2407-9-239.

PMID:
19615087
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.

Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ.

Cancer Lett. 2007 Oct 28;256(2):218-28. Epub 2007 Jul 23.

PMID:
17643814
[PubMed - indexed for MEDLINE]
9.

CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.

Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L, Bliskovsky V, Mock B, Ried T, London WB, Maris J, Khan J, Thiele CJ.

Cell Death Differ. 2011 Jul;18(7):1174-83. doi: 10.1038/cdd.2010.187. Epub 2011 Jan 21.

PMID:
21252912
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.

Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Bénard J, Douc-Rasy S, Cappellen D.

Nucleic Acids Res. 2008 Aug;36(13):4222-32. doi: 10.1093/nar/gkn394. Epub 2008 Jun 25.

PMID:
18583365
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, Molenaar JJ, van Nes J, Versteeg R.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5. doi: 10.1073/pnas.1208215109. Epub 2012 Oct 22.

PMID:
23091029
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma.

Chen ST, Jeng YM, Chang CC, Chang HH, Huang MC, Juan HF, Hsu CH, Lee H, Liao YF, Lee YL, Hsu WM, Lai HS.

Cancer Sci. 2011 Dec;102(12):2191-8. doi: 10.1111/j.1349-7006.2011.02100.x. Epub 2011 Oct 17.

PMID:
21917080
[PubMed - indexed for MEDLINE]
13.

Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.

Schramm A, Köster J, Marschall T, Martin M, Schwermer M, Fielitz K, Büchel G, Barann M, Esser D, Rosenstiel P, Rahmann S, Eggert A, Schulte JH.

Int J Cancer. 2013 Feb 1;132(3):E106-15. doi: 10.1002/ijc.27787. Epub 2012 Sep 26.

PMID:
22907398
[PubMed - indexed for MEDLINE]
14.

Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification.

Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, Fukuzawa M.

Int J Oncol. 2007 May;30(5):1189-96.

PMID:
17390021
[PubMed - indexed for MEDLINE]
15.

Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.

Koppen A, Ait-Aissa R, Koster J, Øra I, Bras J, van Sluis PG, Caron H, Versteeg R, Valentijn LJ.

Int J Cancer. 2008 Apr 1;122(7):1455-64.

PMID:
18059033
[PubMed - indexed for MEDLINE]
16.

Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.

Yamaguchi Y, Takenobu H, Ohira M, Nakazawa A, Yoshida S, Akita N, Shimozato O, Iwama A, Nakagawara A, Kamijo T.

Eur J Cancer. 2014 May;50(8):1555-65. doi: 10.1016/j.ejca.2014.01.023. Epub 2014 Feb 19.

PMID:
24559687
[PubMed - indexed for MEDLINE]
17.

Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.

Henriksen JR, Haug BH, Buechner J, Tømte E, Løkke C, Flaegstad T, Einvik C.

BMC Dev Biol. 2011 Jan 3;11:1. doi: 10.1186/1471-213X-11-1.

PMID:
21194500
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Low expression of Wnt-5a gene is associated with high-risk neuroblastoma.

Blanc E, Roux GL, Bénard J, Raguénez G.

Oncogene. 2005 Feb 10;24(7):1277-83.

PMID:
15592517
[PubMed - indexed for MEDLINE]
19.

PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma.

Yco LP, Geerts D, Koster J, Bachmann AS.

Int J Oncol. 2013 Apr;42(4):1408-16. doi: 10.3892/ijo.2013.1836. Epub 2013 Feb 21.

PMID:
23440329
[PubMed - indexed for MEDLINE]
20.

Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.

Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H, Maris JM, Prendergast GC, Hogarty MD.

Clin Cancer Res. 2003 Aug 15;9(9):3345-55.

PMID:
12960121
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk